PANews reported on March 18th that, according to Fortune, AI cybersecurity startup RunSybil has raised $40 million in funding. The round was led by Khosla VenturesPANews reported on March 18th that, according to Fortune, AI cybersecurity startup RunSybil has raised $40 million in funding. The round was led by Khosla Ventures

RunSybil raises $40 million to automate penetration testing of enterprise software security using AI.

2026/03/18 18:14
1 min read
For feedback or concerns regarding this content, please contact us at [email protected]

PANews reported on March 18th that, according to Fortune, AI cybersecurity startup RunSybil has raised $40 million in funding. The round was led by Khosla Ventures, with participation from S32, Anthropic's Anthology Fund, Menlo Ventures, Conviction, Elad Gil, and angel investors from companies such as OpenAI, Palo Alto Networks, Stripe, and Google. RunSybil uses its AI agent, "Sybil," to perform automated penetration testing on enterprise online applications without human intervention. It can discover, exploit, and record security vulnerabilities in real-world environments. Founded in 2023 by former OpenAI's first security researcher, Ari Herbert-Voss, and former Meta's head of offensive security, Vlad Ionescu, the company currently serves startups and undisclosed financial institutions and Fortune 500 companies.

Market Opportunity
ARI10 Logo
ARI10 Price(ARI)
$0,0003931
$0,0003931$0,0003931
+0,02%
USD
ARI10 (ARI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.